For adult ADHD, stimulants and atomoxetine are the only treatments with robust short-term efficacy, but they do not guarantee improvement in quality of life and lack long-term evidence, while non-pharmacological approaches offer inconsistent results.

noli's read

The creator relies on a major network meta-analysis (Cortese et al., 2018, published in The Lancet Psychiatry), which is indeed a robust reference in the field. The analysis confirms that stimulant medications show the largest effect size on core symptoms in the short term, which is validated by randomized controlled trials (RCT). It is accurate that the literature highlights a gap between symptom reduction (measured by clinical scales) and improvement in perceived overall quality of life, a point often debated in research. Regarding non-pharmacological approaches such as CBT, observational research and meta-analyses confirm heterogeneity in results, often linked to the subjectivity of assessments depending on whether they are reported by the patient or the clinician. The assertion that there is no universal solution and that personalization is necessary is the current scientific consensus. The content is factual and avoids excessive generalizations.

the sources

No named source held this one up — that absence is part of the verdict.